Institute of Good Manufacturing Practices India
Global accredited training provider
Registered under the Societies Registration Act,1860, Government of India
An ISO 9001:2008 Certified Organisation
Permanently empanelled under Ministry of Horticulture and Food Processing, Government of Uttar Pradesh
Conferred with QUALITY COUNCIL OF INDIA (QCI) – D.L. SHAH NATIONAL QUALITY AWARD – Certificate of Merit 2015
New Delhi | Noida | Hyderabad | Lucknow
Trusted by training participants in over 20 countries
Indian active pharmaceutical ingredient (API) manufacturer Megafine Pharma's Nashik site in Maharashtra, India, is now added to the list of foreign manufacturing sites banned from sending products to the US by The US Food and Drug Administration (FDA) on Wednesday.
Megafine, which was hit with an FDA Form 483 back in May at the site, produces 24 APIs for the US market, including for drugs intended to treat Alzheimer's disease, depression, schizophrenia, multiple sclerosis and overactive bladders. The company also produces the same number of APIs for the EU market, as well as a number of other products for Canada, Australia, Brazil, Mexico and South Korea.
The Nashik site, according to the company, has been inspected and approved by regulators including the European Medicines Agency, Japan's Pharmaceutical and Medical Devices Agency, the WHO and others.The notice on Megafine does not indicate the specific issues that caused the import alert and does not indicate if the company's other manufacturing site in Vapi, India will be impacted.
According to a heavily redacted 13-page Form 483, the company was cited for manipulating lab tests, as well as unjustified and unrecorded deviations from written lab mechanisms. The 483 notes that one of the company's quality control (QC) analysts "manipulated" a test chromatogram "by removing the unwanted peak out of the chromatogram and passed off the passing chromatogram as the valid result."
In addition, the FDA inspector found that the QC management could not explain the "wide variation between" an initial test result and a retest result, though, “It is believed that the initial OOS [out of specification] assay was switched with old passing sample vials and retested to obtain the passing test results."
Another QC analyst was cited for manipulating high-performance liquid chromatography software "to obtain passing test results."In addition, FDA found that no "investigation reports were initiated after identification of non-cGMP [current good manufacturing practice] practices within the production and quality control department."
Ranbaxy, Wockhardt and Ipca Laboratories and other forty five Indian pharmaceutical and API manufacturers are on import vigilance presently.